Clinical trials: Monoclonal Antibody
COVID-19
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS)…
- Trial name
- NCT04351243
- Testing
- Gimsilumab
- Where
- 33 sites in United States
- Volunteers
- 227 people
- Sponsor
- Kinevant Sciences GmbH
Hypereosinophilic Syndrome
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
This is a 52-week, randomized, placebo-controlled, double-blind, parallel group, multicenter study of depemokimab in adults with uncontrolled HES receiving standard of care (SoC) therapy.
- Trial name
- DESTINY (NCT05334368)
- Testing
- Depemokimab
- Where
- 60 sites in United States, Argentina and 14 more
- Volunteers
- 110 people
- Sponsor
- GlaxoSmithKline
Contraception
An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film
This is an early Phase 1 study to establish proof-of-concept by determining whether an intravaginal film containing a human contraceptive antibody (ZB-06) shows promise to provide contraceptive efficacy using the post-coital…
- Trial name
- NCT04731818
- Testing
- ZB-06
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- KBio Inc
Rheumatoid Arthritis
An Efficacy and Safety Study of Golimumab in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the efficacy and safety of golimumab, alone or in combination with methotrexate (MTX), as compared to methotrexate alone in rheumatoid arthritis (RA) patients who have active rheumatoid…
- Trial name
- GO-FORWARD (NCT00264550)
- Testing
- Golimumab 100 mg, Golimumab 50 mg, Methotrexate
- Where
- 50 sites in United States, Argentina and 10 more
- Volunteers
- 444 people
- Sponsor
- Centocor, Inc.
Lymphoma
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278408
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 152 sites in Denmark, Germany and 2 more
- Volunteers
- 700 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Solid Tumor, HER-2 Protein Overexpression
Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
This is a Phase 1, open-label, multi-center study to assess safety and determine the recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination with trastuzumab, following lymphodepleting…
- Trial name
- NCT03680560
- Testing
- ACTR T Cell Product, Trastuzumab
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cogent Biosciences, Inc.
Crohn's Disease
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
The purpose of this study is to determine Efficacy, Pharmacokinetics, and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease
- Trial name
- NCT00409682
- Testing
- Adalimumab
- Where
- 45 sites in United States, Belgium and 6 more
- Volunteers
- 192 people
- Sponsor
- Abbott
Advanced Solid Tumor, Solid Tumor
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors.
- Trial name
- NCT05981703
- Testing
- BGB-26808, Tislelizumab, Chemotherapy
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 337 people
- Sponsor
- BeOne Medicines
Breast Cancer
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab
The goal of Phase 1 of this clinical research study is to test the safety and tolerability of AMG 479 when given with trastuzumab.
- Trial name
- NCT01479179
- Testing
- AMG 479, Trastuzumab
- Sponsor
- M.D. Anderson Cancer Center
Small Cell Carcinoma of Esophagus, Advanced Cancer
Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy
To evaluate the anti-tumor activity, safety and tolerance of toripalimab as monotherapy for patients with small cell esophageal cancer (SCCE), and to explore the potential biomarkers for this treatment.
- Trial name
- NCT03811379
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-sen University
Hepatitis B, Chronic
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.
- Trial name
- NCT04133259
- Testing
- Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues
- Where
- 3 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Henlix, Inc
Endometrial Carcinoma
Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
The purpose of this study is to find out whether the addition of a drug called Avastin (avastin) to the two-drug combination of carboplatin and paclitaxel shrinks tumors better than the two-drug combination alone in the treatment…
- Trial name
- NCT00879359
- Testing
- carboplatin, paclitaxel, and bevacizumab
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The Cleveland Clinic
Crohn Disease
The Efficacy of Denosumab in Active Crohn's Disease
Denosumab, a fully human monoclonal antibody to RANKL was approved for the treatment of postmenopausal osteoporosis in June 2010.
- Trial name
- NCT02321280
- Testing
- Denosumab
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of Manitoba
Non-Hodgkin Lymphoma
A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.
- Trial name
- NCT00103779
- Testing
- SGN-40 (anti-huCD40 mAb)
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Seagen Inc.
Ovarian Cancer
A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.
This is an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in combination with Chemotherapy in…
- Trial name
- NCT03763123
- Testing
- Sevacizumab, Paclitaxel, Topotecan
- Where
- 6 sites in China
- Volunteers
- 48 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Systemic Lupus Erythematosus
A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.
- Trial name
- NCT00583362
- Testing
- Belimumab
- Where
- 57 sites in United States, Canada
- Volunteers
- 298 people
- Sponsor
- Human Genome Sciences Inc., a GSK Company
Crohn Disease
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Participants With Crohn's Disease
The purpose of this study is to examine the safety and efficacy of CNTO 1275 in participants with active Crohn's Disease.
- Trial name
- NCT00265122
- Testing
- Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg
- Where
- 57 sites in United States, Belgium and 1 more
- Volunteers
- 131 people
- Sponsor
- Centocor, Inc.
Colorectal Liver Metastases
Folfox-B Study for Patients With Colorectal Liver Metastases
Objective: To evaluate the efficacy of the use of the combination of oxaliplatin, 5-fluorouracil, leucovorin and bevacizumab (FOLFOX-B) in patients with unresectable colorectal liver metastases, with the objective to downstage…
- Trial name
- NCT00508872
- Testing
- 5-Fluorouracil, Bevacizumab, Leucovorin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Cancer
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00311545
- Testing
- CNTO 328
- Sponsor
- SWOG Cancer Research Network
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.